Screening for Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Population Health Perspective
Nov
2026
Description
This community conversation focuses on population health strategies for screening for fibrosis among those at risk for metabolic dysfunction–associated steatotic liver disease (MASLD). Screening for fibrosis among patients with MASLD has been recommended by hepatology, gastroenterology, and endocrinology societies but uptake has been limited.
Presenters with expertise in quality improvement/implementation science address strategies for improving uptake of the FIB-4 elastography pathway in different health care settings. Topics include successful strategies, challenges along the way and strategies to overcome them, limitations of the FIB-4 elastography pathway, and future directions.
Presentations
9:45 AM
- 9:55 AM
Convention Center - Bluebird Ballroom 2GH
Metabolic Dysfunction–Associated Steatotic Liver Disease Fibrosis Screening: Barriers and Strategies
Meagan E Gray, MD | Presenter
9:55 AM
- 10:05 AM
Convention Center - Bluebird Ballroom 2GH
Metabolic Dysfunction–Associated Steatotic Liver Disease Fibrosis Screening: The Primary Care Practitioner Perspective
Rena K Fox, MD | Presenter
10:05 AM
- 10:15 AM
Convention Center - Bluebird Ballroom 2GH
Metabolic Dysfunction–Associated Steatotic Liver Disease Fibrosis Screening: Comparing Implementation Science Strategies
Sujit V. Janardhan, MD, PhD, Dipl ABOM | Presenter
